Developer docs
API playgroundTry for free, no card

Search company profiles

Nuvectis Pharma

Full company profile

uuid0000ct9

Namestring
Nuvectis Pharma
Legal namestring
Nuvectis Pharma, Inc.
Websiteurl
nuvectis.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for complement-mediated diseases and oncology. Founded around 2020-2021 and headquartered in Fort Lee, New Jersey, the company is publicly traded on NASDAQ under the ticker NVCT and operates with a team of 11-50 employees. Nuvectis has no commercialized products and generates no product revenue, relying instead on equity financing and licensing arrangements to fund operations.

The company's pipeline consists of four oral small-molecule drug candidates, each with a differentiated mechanism of action. NXP900 is a Type 1.5 SRC Family Kinase inhibitor that achieves complete shutdown of SRC signaling by inhibiting both catalytic and scaffolding functions, currently advancing through Phase 1b trials in advanced solid tumors and showing preclinical synergy with sotorasib in NSCLC models. NXP800 is a GCN2 activator licensed from the CRT Pioneer Fund, evaluated for platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma. In June 2026, Nuvectis significantly expanded its pipeline through a licensing deal with Haisco Pharmaceutical Group, adding NXP100 (a Complement Factor B inhibitor for PNH, IgAN, lupus nephritis, and other complement-mediated conditions) and NXP200 (a paradox-breaker BRAF inhibitor for Class I/II/III BRAF-mutated malignancies).

Nuvectis's business model centers on licensing intellectual property from research institutions and pharmaceutical partners, advancing candidates through clinical trials, and ultimately monetizing through milestone payments, royalties, or potential commercialization partnerships. The company has raised approximately $61.7 million cumulatively across private placements (October 2021, July 2022), a Series A (June 2024), and a post-IPO public offering (February 2025). The June 2026 Haisco agreement is the largest commercial transaction in the company's history, with up to $40 million in upfront and near-term payments plus up to $1.421 billion in potential milestones and tiered royalties. Patient segments addressed include those suffering from complement-mediated rare and orphan diseases and from hard-to-treat solid tumors including EGFR-mutated NSCLC, ARID1a-mutated ovarian cancer, cholangiocarcinoma, and BRAF-mutated malignancies.

Short descriptiontext

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing four oral small-molecule drug candidates for complement-mediated diseases and oncology. The publicly traded firm (NASDAQ: NVCT) licenses precision medicines from Haisco and CRT Pioneer Fund and has no commercialized products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersFort Lee, United States
HQ citystring
Fort Lee
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology medicines, kinase inhibitor drugs, complement pathway therapeutics, biopharmaceutical drug development, cancer therapeutics pipeline
Industry3 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals (Precision Oncology and Complement Therapeutics)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

As a clinical-stage biopharmaceutical company, Nuvectis generates revenue through licensing agreements that include upfront payments, development/regulatory/commercial milestone payments, and tiered royalties on net sales of approved products. The company has no commercialized products and is not yet profitable.

financialcontent.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for the treatment of oncology and complement-related diseases. Its pipeline includes four drug candidates: NXP900 (SRC Family Kinase inhibitor), NXP800 (GCN2 kinase activator), NXP100 (Complement Factor B inhibitor), and NXP200 (paradox-breaker BRAF inhibitor), all in-licensed from research and pharmaceutical partners and advanced through clinical trials toward regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NXP100 showed Phase 3 efficacy superior to C5 inhibitors like Soliris in PNH treatment
+2 more records
Product overview1 text field

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing a portfolio of precision medicines for complement-related conditions and oncology. The company's pipeline includes four drug candidates: NXP900 (SRC/YES1 kinase inhibitor for solid tumors), NXP800 (GCN2 kinase activator for ovarian cancer and cholangiocarcinoma), NXP100 (Complement Factor B inhibitor for complement-mediated diseases including PNH and IgAN), and NXP200 (paradox-breaker BRAF inhibitor for BRAF-mutated malignancies).

Product and service4 records
1NXP900
CategoryPrecision Oncology - Kinase Inhibitor
Description

Oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1, with a Type 1.5 mechanism of action that inhibits both catalytic and scaffolding functions of SRC kinase for complete signaling pathway shutdown. Completed dose escalation in advanced solid tumors and a drug-drug interaction study; in Phase 1b program as single agent and in combination with other anti-cancer agents.

2NXP800
CategoryPrecision Oncology - Kinase Activator
Description

Oral small molecule activator of the kinase GCN2, evaluated for the treatment of platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma (with an investigator-sponsored trial led by Mayo Clinic). Demonstrated biologic activity in Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer.

3NXP100
CategoryComplement Therapeutics - Factor B Inhibitor
Description

Oral, once-daily small molecule inhibitor of Complement Factor B, a critical protease within the alternative pathway of the complement cascade. Halts formation and stabilization of the C3 convertase and its positive feedback amplification loop. In development for paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), lupus nephritis, C3 glomerulonephritis, myasthenia gravis, and dry age-related macular degeneration. Phase 3 data demonstrated efficacy superior to C5 inhibitors like Soliris in PNH.

4NXP200
CategoryPrecision Oncology - BRAF Inhibitor
Description

Oral small-molecule paradox-breaker BRAF inhibitor that circumvents paradoxical activation caused by first-generation BRAF inhibitors by physically disrupting BRAF dimer formation. Targets Class I, Class II, and Class III BRAF mutations across multiple tumor types.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Haisco Pharmaceutical Group
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Nuvectis entered into a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds: NXP100 (Complement Factor B inhibitor) and NXP200 (BRAF inhibitor). Haisco will receive up to $40 million in upfront and near-term payments, with potential milestone payments up to $1.421 billion plus tiered royalties on net sales. This deal transforms Nuvectis into a late-stage clinical development company.

financialcontent.com
2CRT Pioneer Fund
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-06-04
Description

Nuvectis licensed exclusive rights to develop NXP800, a novel cancer drug candidate, from the CRT Pioneer Fund. The company aims to advance NXP800 through clinical trials targeting hard-to-treat solid tumors, building on research from the Institute for Cancer Research UK.

drug-dev.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research foundation whose work underlies the NXP800 drug candidate licensed from CRT Pioneer Fund. Nuvectis builds on research from this institute for cancer drug development.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing complement inhibitors including Empaveli (pegcetacoplan) for PNH, directly competing with Nuvectis's NXP100 in the same indication via a different pathway (C3 vs Factor B).

TypeDirect peer
Description

Clinical-stage precision oncology company developing targeted small molecule inhibitors for difficult-to-treat solid tumors, comparable in stage, approach, and target patient population to Nuvectis's NXP900 and NXP800 programs.

TypeDirect peer
Description

Precision oncology company developing next-generation kinase inhibitors including BRAF-targeted therapies, directly comparable to Nuvectis's NXP200 paradox-breaker BRAF inhibitor program.

TypeDirect peer
Description

Clinical-stage precision oncology company using structure-based drug design to develop targeted therapies for solid tumors, comparable in stage and precision-medicine approach to Nuvectis.

TypeDirect peer
Description

Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway-driven cancers, directly comparable in mechanism and target patient population to Nuvectis's kinase inhibitor programs.

TypeBroad incumbent
Description

Established leader in PNH and complement-mediated diseases with Soliris and Ultomiris (C5 inhibitors), represents the entrenched competitor that NXP100 aims to disrupt with oral Factor B inhibition.

TypeDirect peer
Description

Clinical-stage biopharma developing targeted oral small molecule therapies for rare endocrine diseases, comparable in company stage, oral small molecule approach, and rare-disease focus to Nuvectis.

TypeDirect peer
Description

Clinical-stage precision oncology company developing novel targeted protein degraders, comparable in clinical stage and precision medicine approach targeting difficult oncology indications like Nuvectis.

TypeDirect peer
Description

Clinical-stage biopharma with complement inhibitor programs including narsoplimab for IgA nephropathy and other complement-mediated diseases, directly comparable to Nuvectis's NXP100 indication set.

TypeBroad incumbent
Description

Larger clinical-stage biopharma developing targeted therapies for rare genetic diseases, comparable in precision-medicine philosophy and rare-disease focus to Nuvectis's complement pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuvectis Pharma

Clinical-stage Biopharmaceuticals (Precision Oncology and Complement Therapeutics)nuvectis.com

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing four oral small-molecule drug candidates for complement-mediated diseases and oncology. The publicly traded firm (NASDAQ: NVCT) licenses precision medicines from Haisco and CRT Pioneer Fund and has no commercialized products.

What Nuvectis Pharma does

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for complement-mediated diseases and oncology. Founded around 2020-2021 and headquartered in Fort Lee, New Jersey, the company is publicly traded on NASDAQ under the ticker NVCT and operates with a team of 11-50 employees. Nuvectis has no commercialized products and generates no product revenue, relying instead on equity financing and licensing arrangements to fund operations.

The company's pipeline consists of four oral small-molecule drug candidates, each with a differentiated mechanism of action. NXP900 is a Type 1.5 SRC Family Kinase inhibitor that achieves complete shutdown of SRC signaling by inhibiting both catalytic and scaffolding functions, currently advancing through Phase 1b trials in advanced solid tumors and showing preclinical synergy with sotorasib in NSCLC models. NXP800 is a GCN2 activator licensed from the CRT Pioneer Fund, evaluated for platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma. In June 2026, Nuvectis significantly expanded its pipeline through a licensing deal with Haisco Pharmaceutical Group, adding NXP100 (a Complement Factor B inhibitor for PNH, IgAN, lupus nephritis, and other complement-mediated conditions) and NXP200 (a paradox-breaker BRAF inhibitor for Class I/II/III BRAF-mutated malignancies).

Nuvectis's business model centers on licensing intellectual property from research institutions and pharmaceutical partners, advancing candidates through clinical trials, and ultimately monetizing through milestone payments, royalties, or potential commercialization partnerships. The company has raised approximately $61.7 million cumulatively across private placements (October 2021, July 2022), a Series A (June 2024), and a post-IPO public offering (February 2025). The June 2026 Haisco agreement is the largest commercial transaction in the company's history, with up to $40 million in upfront and near-term payments plus up to $1.421 billion in potential milestones and tiered royalties. Patient segments addressed include those suffering from complement-mediated rare and orphan diseases and from hard-to-treat solid tumors including EGFR-mutated NSCLC, ARID1a-mutated ovarian cancer, cholangiocarcinoma, and BRAF-mutated malignancies.

Nuvectis Pharma firmographics

Firmographics
Name
Nuvectis Pharma
Legal name
Nuvectis Pharma, Inc.
Website
https://nuvectis.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Nuvectis Pharma is a clinical-stage biopharmaceutical company developing four oral small-molecule drug candidates for complement-mediated diseases and oncology. The publicly traded firm (NASDAQ: NVCT) licenses precision medicines from Haisco and CRT Pioneer Fund and has no commercialized products.
Ownership category
akta.pro rank

Nuvectis Pharma industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (Precision Oncology and Complement Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Precision oncology medicines
  • Kinase inhibitor drugs
  • Complement pathway therapeutics
  • Biopharmaceutical drug development
  • Cancer therapeutics pipeline

Where Nuvectis Pharma is headquartered

Location

Headquarters

HQ city
Fort Lee
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nuvectis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: As a clinical-stage biopharmaceutical company, Nuvectis generates revenue through licensing agreements that include upfront payments, development/regulatory/commercial milestone payments, and tiered royalties on net sales of approved products. The company has no commercialized products and is not yet profitable.

Go-to-market motion1 record

Marketing channels3 records

Nuvectis Pharma product offering

Product offering

Core offering

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for the treatment of oncology and complement-related diseases. Its pipeline includes four drug candidates: NXP900 (SRC Family Kinase inhibitor), NXP800 (GCN2 kinase activator), NXP100 (Complement Factor B inhibitor), and NXP200 (paradox-breaker BRAF inhibitor), all in-licensed from research and pharmaceutical partners and advanced through clinical trials toward regulatory approval.

Product overview

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing a portfolio of precision medicines for complement-related conditions and oncology. The company's pipeline includes four drug candidates: NXP900 (SRC/YES1 kinase inhibitor for solid tumors), NXP800 (GCN2 kinase activator for ovarian cancer and cholangiocarcinoma), NXP100 (Complement Factor B inhibitor for complement-mediated diseases including PNH and IgAN), and NXP200 (paradox-breaker BRAF inhibitor for BRAF-mutated malignancies).

Differentiator

Problem solved

Functional benefit

Products and services

  • NXP900 Oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1, with a Type 1.5 mechanism of action that inhibits both catalytic and scaffolding functions of SRC kinase for complete signaling pathway shutdown. Completed dose escalation in advanced solid tumors and a drug-drug interaction study; in Phase 1b program as single agent and in combination with other anti-cancer agents.
  • NXP800 Oral small molecule activator of the kinase GCN2, evaluated for the treatment of platinum-resistant ARID1a-mutated ovarian cancer and cholangiocarcinoma (with an investigator-sponsored trial led by Mayo Clinic). Demonstrated biologic activity in Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer.
  • NXP100 Oral, once-daily small molecule inhibitor of Complement Factor B, a critical protease within the alternative pathway of the complement cascade. Halts formation and stabilization of the C3 convertase and its positive feedback amplification loop. In development for paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy (IgAN), lupus nephritis, C3 glomerulonephritis, myasthenia gravis, and dry age-related macular degeneration. Phase 3 data demonstrated efficacy superior to C5 inhibitors like Soliris in PNH.
  • NXP200 Oral small-molecule paradox-breaker BRAF inhibitor that circumvents paradoxical activation caused by first-generation BRAF inhibitors by physically disrupting BRAF dimer formation. Targets Class I, Class II, and Class III BRAF mutations across multiple tumor types.

Quantifiable outcome

  • NXP100 showed Phase 3 efficacy superior to C5 inhibitors like Soliris in PNH treatment
  • +2 more outcomes

Companies that use Nuvectis Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Nuvectis Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Nuvectis Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Haisco Pharmaceutical GroupcoreStrategic or Co-development Partner · 22 June 2026Nuvectis entered into a license agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds: NXP100 (Complement Factor B inhibitor) and NXP200 (BRAF inhibitor). Haisco will receive up to $40 million in upfront and near-term payments, with potential milestone payments up to $1.421 billion plus tiered royalties on net sales. This deal transforms Nuvectis into a late-stage clinical development company.
  • CRT Pioneer FundcoreOEM/ Whitelabel/ Licensing Partner · 4 June 2024Nuvectis licensed exclusive rights to develop NXP800, a novel cancer drug candidate, from the CRT Pioneer Fund. The company aims to advance NXP800 through clinical trials targeting hard-to-treat solid tumors, building on research from the Institute for Cancer Research UK.
  • Institute for Cancer Research UKminorStrategic or Co-development PartnerResearch foundation whose work underlies the NXP800 drug candidate licensed from CRT Pioneer Fund. Nuvectis builds on research from this institute for cancer drug development.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Nuvectis Pharma competitors and assessment

Company assessment

Direct peers

  • Apellis Pharmaceuticals: Clinical-stage biopharma developing complement inhibitors including Empaveli (pegcetacoplan) for PNH, directly competing with Nuvectis's NXP100 in the same indication via a different pathway (C3 vs Factor B).
  • Revolution Medicines: Clinical-stage precision oncology company developing targeted small molecule inhibitors for difficult-to-treat solid tumors, comparable in stage, approach, and target patient population to Nuvectis's NXP900 and NXP800 programs.
  • Black Diamond Therapeutics: Precision oncology company developing next-generation kinase inhibitors including BRAF-targeted therapies, directly comparable to Nuvectis's NXP200 paradox-breaker BRAF inhibitor program.
  • Relay Therapeutics: Clinical-stage precision oncology company using structure-based drug design to develop targeted therapies for solid tumors, comparable in stage and precision-medicine approach to Nuvectis.
  • Erasca: Clinical-stage precision oncology company developing kinase inhibitors for RAS/MAPK pathway-driven cancers, directly comparable in mechanism and target patient population to Nuvectis's kinase inhibitor programs.
  • Crinetics Pharmaceuticals: Clinical-stage biopharma developing targeted oral small molecule therapies for rare endocrine diseases, comparable in company stage, oral small molecule approach, and rare-disease focus to Nuvectis.
  • Arvinas: Clinical-stage precision oncology company developing novel targeted protein degraders, comparable in clinical stage and precision medicine approach targeting difficult oncology indications like Nuvectis.
  • Omeros Corporation: Clinical-stage biopharma with complement inhibitor programs including narsoplimab for IgA nephropathy and other complement-mediated diseases, directly comparable to Nuvectis's NXP100 indication set.

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Established leader in PNH and complement-mediated diseases with Soliris and Ultomiris (C5 inhibitors), represents the entrenched competitor that NXP100 aims to disrupt with oral Factor B inhibition.
  • BridgeBio Pharma: Larger clinical-stage biopharma developing targeted therapies for rare genetic diseases, comparable in precision-medicine philosophy and rare-disease focus to Nuvectis's complement pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Nuvectis Pharma social profiles

Digital presence

Nuvectis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuvectis Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Nuvectis Pharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuvectis Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuvectis Pharma

What does Nuvectis Pharma do?

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule precision medicines for the treatment of oncology and complement-related diseases. Its pipeline includes four drug candidates: NXP900 (SRC Family Kinase inhibitor), NXP800 (GCN2 kinase activator), NXP100 (Complement Factor B inhibitor), and NXP200 (paradox-breaker BRAF inhibitor), all in-licensed from research and pharmaceutical partners and advanced through clinical trials toward regulatory approval.

Is Nuvectis Pharma a public or private company?

Nuvectis Pharma is a public company. It is classified as public and is currently operating.

When was Nuvectis Pharma founded?

Nuvectis Pharma was founded in 2021. It employs 1 to 10 people.

Where is Nuvectis Pharma based?

Nuvectis Pharma is headquartered in Fort Lee, United States, in the North America region.

How does Nuvectis Pharma make money?

One revenue line is on record: licensing and Milestone Payments.

Who are Nuvectis Pharma's main competitors?

Direct peers on record are Apellis Pharmaceuticals, Revolution Medicines, Black Diamond Therapeutics, Relay Therapeutics, Erasca, Crinetics Pharmaceuticals, Arvinas and Omeros Corporation. Broad incumbents are Alexion (AstraZeneca Rare Disease) and BridgeBio Pharma.

Does Nuvectis Pharma have an API?

No public API is recorded for Nuvectis Pharma.

What industry is Nuvectis Pharma in?

Nuvectis Pharma's product category is Clinical-stage Biopharmaceuticals (Precision Oncology and Complement Therapeutics). Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaNuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call TranscriptNuvectis Pharma held its Q3 2026 earnings call on November 4, 2026, with CEO Ron Bentsur leading. The call was the first time the company hosted a call alongside quarterly results, and the third quarter was described as transformational. Forward-looking statements were made, with risks referenced in the 10-Q.MarketScreenerNuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Nuvectis Pharma reported a Q3 net loss of $30.07 million and a nine-month net loss of $43.14 million, both worse than the prior year. Basic and diluted loss per share from continuing operations were $1.02 and $1.69 respectively, compared to $0.44 and $1.01 a year ago.TradingViewNuvectis Pharma Reports Q3 2026 Net Loss of $30.1 Million and $140.7 Million in CashNuvectis Pharma reported a Q3 2026 net loss of $30.1 million and ended September with $140.7 million in cash. The quarter included a $20 million upfront license payment and $1.8 million in milestones, with ciprocopan approved in China and U.S. regulatory discussions ongoing.American Banking and Market NewsNuvectis Pharma (NVCT) Expected to Post Quarterly Earnings on TuesdayNuvectis Pharma is expected to report Q3 2026 earnings on Tuesday, with analysts projecting a loss of $0.22 per share. The company previously missed estimates with a $0.30 loss, and analysts have set an average price target of $36.25.InvestegateNuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT)Nuvectis reported four complete responses and tumor shrinkage in 22 of 27 patients with BRAF V600-mutated gliomas in a Phase 1b study of NXP200. The results, presented at ESMO, show a 40% response rate in high-grade disease and support continued development. The company expects further Phase 1b updates in additional tumor types.MarketBeatNuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Average Target Price of $36.25 According to BrokeragesNuvectis Pharma stock received an average Moderate Buy rating from five analysts, with a 1-year price target of $36.25. Institutional investors own 96.77% of the company, and the stock opened at $20.05. The company reported a Q2 loss of $0.30 per share, missing the consensus estimate.InvestegateNuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead AssetNuvectis Pharma's oral BRAF inhibitor NXP200 received Breakthrough Therapy Designation in China for BRAF V600-mutant high-grade glioma, following a dose-escalation study with over 40% response rates. The company also holds ex-China rights to ciprocopan, approved in China for PNH, and plans U.S. IND submissions in Q4.Ticker ReportNuvectis Pharma (NASDAQ:NVCT) Upgraded by Lucid Cap Mkts to “Strong-Buy” RatingLucid Cap Mkts upgraded Nuvectis Pharma to a strong-buy rating on Tuesday. The stock opened at $24.37, with an average analyst rating of Moderate Buy and a target price of $36.25. The company reported a loss of $0.30 per share for the quarter, missing estimates.Investing.comLucid Capital Markets initiates Nuvectis Pharma stock with buy rating By Investing.comLucid Capital Markets initiated coverage on Nuvectis Pharma with a buy rating and a $40 price target, citing a 76% upside from the current $22.73 price. The firm estimates $1 billion in U.S. sales by 2035 and $750 million in EU5 by 2036, with a 80% success probability. Nuvectis recently raised $100 million via a 30% discount offering.Investing.comLucid Capital Markets initiates Nuvectis Pharma stock with buy rating By Investing.comLucid Capital Markets initiated coverage on Nuvectis Pharma with a buy rating and a $40 price target, citing a 76% upside from the current $22.73 price. The firm estimates $1 billion in U.S. sales by 2035 and $750 million in EU5 by 2036, with a 80% success probability. Nuvectis recently raised $100 million in a public offering.